|
|
|
|
| LEADER |
05566nma a2201513 u 4500 |
| 001 |
EB002194314 |
| 003 |
EBX01000000000000001331779 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
240202 ||| eng |
| 020 |
|
|
|a 9783036587974
|
| 020 |
|
|
|a 9783036587967
|
| 020 |
|
|
|a books978-3-0365-8796-7
|
| 100 |
1 |
|
|a Otero-Espinar, Francisco Javier
|
| 245 |
0 |
0 |
|a Ophthalmic Drug Delivery
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
| 300 |
|
|
|a 1 electronic resource (330 p.)
|
| 653 |
|
|
|a cytotoxicity studies
|
| 653 |
|
|
|a RGD peptide
|
| 653 |
|
|
|a CNTF
|
| 653 |
|
|
|a intravitreal delivery
|
| 653 |
|
|
|a gelatin
|
| 653 |
|
|
|a retinal penetration
|
| 653 |
|
|
|a gene therapy
|
| 653 |
|
|
|a eyelid
|
| 653 |
|
|
|a retinitis pigmentosa
|
| 653 |
|
|
|a excitotoxicity
|
| 653 |
|
|
|a Ozurdex
|
| 653 |
|
|
|a USP apparatus 4
|
| 653 |
|
|
|a lysosomal trapping
|
| 653 |
|
|
|a mucin
|
| 653 |
|
|
|a triamcinolone acetonide
|
| 653 |
|
|
|a glaucoma
|
| 653 |
|
|
|a tolerance
|
| 653 |
|
|
|a sustained delivery system
|
| 653 |
|
|
|a ophthalmic solution
|
| 653 |
|
|
|a neuroprotection
|
| 653 |
|
|
|a in vitro model
|
| 653 |
|
|
|a epigallocatechin gallate (EGCG)
|
| 653 |
|
|
|a PLGA
|
| 653 |
|
|
|a plasmid electrotransfection
|
| 653 |
|
|
|a neurodegeneration
|
| 653 |
|
|
|a atropine
|
| 653 |
|
|
|a therapeutic proteins
|
| 653 |
|
|
|a dry eye
|
| 653 |
|
|
|a periocular administration
|
| 653 |
|
|
|a fungal keratitis
|
| 653 |
|
|
|a Schlemm's canal
|
| 653 |
|
|
|a amphotericin B
|
| 653 |
|
|
|a hydrogels
|
| 653 |
|
|
|a age-related macular degeneration
|
| 653 |
|
|
|a γ-cyclodextrins
|
| 653 |
|
|
|a stability
|
| 653 |
|
|
|a macular edema
|
| 653 |
|
|
|a SLA 3D-printing
|
| 653 |
|
|
|a controlled drug release
|
| 653 |
|
|
|a topical administration
|
| 653 |
|
|
|a ocular drug delivery systems
|
| 653 |
|
|
|a biotin-decorated nanoparticles
|
| 653 |
|
|
|a dexamethasone
|
| 653 |
|
|
|a microspheres
|
| 653 |
|
|
|a half-life extension
|
| 653 |
|
|
|a drug delivery
|
| 653 |
|
|
|a targeted therapy
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a lutein
|
| 653 |
|
|
|a myopia
|
| 653 |
|
|
|a PLGA microspheres
|
| 653 |
|
|
|a retina
|
| 653 |
|
|
|a anti-angiogenesis
|
| 653 |
|
|
|a drug delivery systems
|
| 653 |
|
|
|a polymeric nanoparticles
|
| 653 |
|
|
|a radiolabeled ocular biopermanence
|
| 653 |
|
|
|a poly(lactic-co-glycolic) acid
|
| 653 |
|
|
|a gamma sterilization
|
| 653 |
|
|
|a intravitreal injection
|
| 653 |
|
|
|a corneal neovascularization (NV)
|
| 653 |
|
|
|a rheology
|
| 653 |
|
|
|a transport
|
| 653 |
|
|
|a protein aggregation
|
| 653 |
|
|
|a intravitreal injections
|
| 653 |
|
|
|a ophthalmology
|
| 653 |
|
|
|a transferrin
|
| 653 |
|
|
|a ARPE-19
|
| 653 |
|
|
|a retinal pigment epithelium
|
| 653 |
|
|
|a dissolution
|
| 653 |
|
|
|a trabecular meshwork
|
| 653 |
|
|
|a cyclodextrins
|
| 653 |
|
|
|a albumin
|
| 653 |
|
|
|a hyaluronic acid (HA), nanoparticles
|
| 653 |
|
|
|a cationic drug
|
| 653 |
|
|
|a size exclusion chromatography
|
| 653 |
|
|
|a USP apparatus 7
|
| 653 |
|
|
|a transcorneal permeation
|
| 653 |
|
|
|a PLGA-PEG-biotin
|
| 653 |
|
|
|a Manufacturing industries / bicssc
|
| 653 |
|
|
|a ocular routes of drug administration
|
| 653 |
|
|
|a in vitro drug release
|
| 653 |
|
|
|a rebamipide
|
| 653 |
|
|
|a iron
|
| 653 |
|
|
|a intravitreal implants
|
| 653 |
|
|
|a microparticles
|
| 653 |
|
|
|a dexamethasone acetate
|
| 653 |
|
|
|a ocular drug delivery
|
| 653 |
|
|
|a retinal degeneration
|
| 653 |
|
|
|a corticosteroids
|
| 653 |
|
|
|a eye drops
|
| 653 |
|
|
|a intravitreal administration
|
| 653 |
|
|
|a blood-retinal barrier
|
| 653 |
|
|
|a intravitreal dexamethasone implant
|
| 653 |
|
|
|a ocular pharmacokinetics
|
| 653 |
|
|
|a fasudil
|
| 653 |
|
|
|a ROCK inhibitor
|
| 653 |
|
|
|a vitreous substitute
|
| 653 |
|
|
|a Electric Cell-Substrate Impedance Sensing
|
| 700 |
1 |
|
|a Ferreiro, Anxo Fernández
|
| 700 |
1 |
|
|a Otero-Espinar, Francisco Javier
|
| 700 |
1 |
|
|a Ferreiro, Anxo Fernández
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-8796-7
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/128629
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/8081
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 580
|
| 082 |
0 |
|
|a 380
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a Research in ophthalmic drug delivery has developed significant advances in the last few years, and efforts have been made to develop more effective topical formulations to increase drug bioavailability, efficiency, and safety. Drug delivery to the posterior segment of the eye remains a great challenge in the pharmaceutical industry due to the complexity and particularity of the eye's anatomy and physiology. Some advances have been made with the purpose of maintaining constant drug levels in the site of action. The anatomical ocular barriers have a great impact on drug pharmacokinetics and, subsequently, on the pharmacological effect.Despite the increasing interest in efficiently reaching the posterior segment of the eye with reduced adverse effects, there is still a need to expand the knowledge of ocular pharmacokinetics that allow the development of safer and more innovative drug delivery systems. These novel approaches may greatly improve the lives of patients with ocular pathologies.
|